应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
NUVL Nuvalent, Inc.
盘后交易 02-27 17:36:40 EST
101.95
-1.98
-1.91%
盘后
101.95
+0.00
0.00%
17:21 EST
最高
103.63
最低
100.25
成交量
66.87万
今开
102.96
昨收
103.93
日振幅
3.25%
总市值
79.17亿
流通市值
48.81亿
总股本
7,766万
成交额
6,801万
换手率
1.40%
流通股本
4,787万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Nuvalent公布近期研发管线进展，重申关键预期里程碑，并报告2025年第四季度及全年财务业绩
美股速递 · 02-26 19:32
Nuvalent公布近期研发管线进展，重申关键预期里程碑，并报告2025年第四季度及全年财务业绩
Nuvalent, Inc.跌0.40% 股价跌破100美元大关
市场透视 · 2025-12-31
Nuvalent, Inc.跌0.40% 股价跌破100美元大关
Nuvalent, Inc.盘中异动 大幅拉升5.06%报112.55美元
市场透视 · 2025-11-20
Nuvalent, Inc.盘中异动 大幅拉升5.06%报112.55美元
Nuvalent宣布FDA接受Zidesamtinib的新药申请，用于治疗已接受TKI治疗的晚期ROS1阳性NSCLC患者
美股速递 · 2025-11-20
Nuvalent宣布FDA接受Zidesamtinib的新药申请，用于治疗已接受TKI治疗的晚期ROS1阳性NSCLC患者
全球股市概览：市场动态
投资观察 · 2025-11-18
全球股市概览：市场动态
Nuvalent：计划在预 NDA 会议上与 FDA 讨论 TKI 预治疗 ALK 阳性 NSCLC 人群的关键数据
美股速递 · 2025-11-17
Nuvalent：计划在预 NDA 会议上与 FDA 讨论 TKI 预治疗 ALK 阳性 NSCLC 人群的关键数据
Nuvalent：Neladalkib展现出良好的耐受性安全特征，剂量中断和剂量减少发生率低
美股速递 · 2025-11-17
Nuvalent：Neladalkib展现出良好的耐受性安全特征，剂量中断和剂量减少发生率低
Nuvalent在253名ALK TKI预处理患者中的ORR为31%，估计18个月时53%的应答者仍保持反应
美股速递 · 2025-11-17
Nuvalent在253名ALK TKI预处理患者中的ORR为31%，估计18个月时53%的应答者仍保持反应
Nuvalent公布ALK阳性晚期非小细胞肺癌TKI预处理患者的ALKOVE-1临床试验Neladalkib的关键数据时间安排
美股速递 · 2025-11-15
Nuvalent公布ALK阳性晚期非小细胞肺癌TKI预处理患者的ALKOVE-1临床试验Neladalkib的关键数据时间安排
华尔街顶级分析师最新评级报告：美国电话电报公司评级上调
环球市场播报 · 2025-11-12
华尔街顶级分析师最新评级报告：美国电话电报公司评级上调
Nuvalent, Inc.跌2.98% 股价跌破100美元大关
市场透视 · 2025-10-31
Nuvalent, Inc.跌2.98% 股价跌破100美元大关
Nuvalent, Inc. - 预计将在2025年底报告Neladalkib在已接受TKI治疗的晚期ALK阳性非小细胞肺癌中的关键临床数据
美股速递 · 2025-10-30
Nuvalent, Inc. - 预计将在2025年底报告Neladalkib在已接受TKI治疗的晚期ALK阳性非小细胞肺癌中的关键临床数据
Nuvalent强调近期管道进展，重申关键预期里程碑，并报告2025年第三季度财务业绩
美股速递 · 2025-10-30
Nuvalent强调近期管道进展，重申关键预期里程碑，并报告2025年第三季度财务业绩
Nuvalent, Inc.盘中异动 下午盘股价大跌5.08%报92.24美元
市场透视 · 2025-10-23
Nuvalent, Inc.盘中异动 下午盘股价大跌5.08%报92.24美元
Nuvalent, Inc.盘中异动 急速上涨5.11%
市场透视 · 2025-10-21
Nuvalent, Inc.盘中异动 急速上涨5.11%
Nuvalent, Inc.盘中异动 下午盘股价大跌5.35%
市场透视 · 2025-10-15
Nuvalent, Inc.盘中异动 下午盘股价大跌5.35%
Nuvalent, Inc.在2025年世界肺癌大会上公布Zidesamtinib治疗既往接受TKI治疗的晚期ROS1阳性非小细胞肺癌患者的Arros-1临床试验关键数据
美股速递 · 2025-09-07
Nuvalent, Inc.在2025年世界肺癌大会上公布Zidesamtinib治疗既往接受TKI治疗的晚期ROS1阳性非小细胞肺癌患者的Arros-1临床试验关键数据
Nuvalent, Inc.盘中异动 急速下挫5.08%报67.46美元
市场透视 · 2025-03-11
Nuvalent, Inc.盘中异动 急速下挫5.08%报67.46美元
Nuvalent, Inc.2024财年实现净利润-2.61亿美元，同比减少107.14%
市场透视 · 2025-03-07
Nuvalent, Inc.2024财年实现净利润-2.61亿美元，同比减少107.14%
Nuvalent 2024年第四季度每股亏损1.05美元，超出分析师预期的1.08美元
财报速递 · 2025-02-27
Nuvalent 2024年第四季度每股亏损1.05美元，超出分析师预期的1.08美元
加载更多
公司概况
公司名称：
Nuvalent, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Nuvalent, Inc.于2017年1月25日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。该公司利用团队在化学和基于结构的药物设计方面的深厚专业知识，开发创新的小分子，其设计旨在克服现有疗法对临床证明的激酶靶点的限制。目前可用的激酶抑制剂面临的限制可能包括（i）激酶耐药性，或激酶靶点出现新的突变，从而能够对现有疗法产生耐药性，（ii）激酶选择性，或现有疗法可能抑制结构相似的激酶靶点并导致脱靶不良事件，以及（iii）有限的脑外显率，或该疗法治疗已经扩散或转移到大脑的疾病的能力。
发行价格：
--
{"stockData":{"symbol":"NUVL","market":"US","secType":"STK","nameCN":"Nuvalent, Inc.","latestPrice":101.95,"timestamp":1772226000000,"preClose":103.93,"halted":0,"volume":668676,"hourTrading":{"tag":"盘后","latestPrice":101.95,"preClose":101.95,"latestTime":"17:21 EST","volume":68706,"amount":7004142.47808,"timestamp":1772230871212,"change":0,"changeRate":0,"amplitude":0.000785},"delay":0,"changeRate":-0.0190512845184259,"floatShares":47871700,"shares":77657211,"eps":-5.320026,"marketStatus":"盘后交易","change":-1.98,"latestTime":"02-27 17:36:40 EST","open":102.96,"high":103.63,"low":100.25,"amount":68009076.73932,"amplitude":0.032522,"askPrice":103.97,"askSize":19,"bidPrice":101.98,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-5.320026,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772240400000},"marketStatusCode":4,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":103.93,"postHourTrading":{"tag":"盘后","latestPrice":101.95,"preClose":101.95,"latestTime":"17:21 EST","volume":68706,"amount":7004142.47808,"timestamp":1772230871212,"change":0,"changeRate":0,"amplitude":0.000785},"volumeRatio":1.284664,"impliedVol":0.4336,"impliedVolPercentile":0.3665},"requestUrl":"/m/hq/s/NUVL","defaultTab":"news","newsList":[{"id":"1160862794","title":"Nuvalent公布近期研发管线进展，重申关键预期里程碑，并报告2025年第四季度及全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1160862794","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160862794?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:32","pubTimestamp":1772105558,"startTime":"0","endTime":"0","summary":"Nuvalent, Inc. (纳斯达克代码: NUVL) 近日披露了其研发管线的最新动态，再次强调了未来重要的预期里程碑节点，同时公布了公司2025财年第四季度及全年的财务业绩报告。\n公司管理层详细介绍了其在研项目取得的实质性进展，特别是在靶向疗法领域。这些进展进一步巩固了其在精准肿瘤学药物开发方面的领先地位。与此同时，财务数据显示了公司在战略投资研发与维持财务健康之间取得的平衡。\n此次信息更新为投资者和行业观察人士提供了评估公司未来发展轨迹和潜在价值的关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","NUVL"],"gpt_icon":0},{"id":"2600308304","title":"Nuvalent, Inc.跌0.40% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2600308304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600308304?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:31","pubTimestamp":1767191464,"startTime":"0","endTime":"0","summary":"北京时间2025年12月31日22时31分，Nuvalent, Inc.股票出现波动，股价快速跳水0.40%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Vanda Pharmaceuticals Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Fibrobiologics, Inc.、Gri Bio, Inc.、Pmgc Holdings Inc.较为活跃，换手率分别为22.66%、14.08%、14.01%，振幅较大的相关个股有Gri Bio, Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Outlook Therapeutics, Inc.，振幅分别为7.66%、7.41%、5.90%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231223105a6e5f6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231223105a6e5f6fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NUVL","BK4539"],"gpt_icon":0},{"id":"2585403198","title":"Nuvalent, Inc.盘中异动 大幅拉升5.06%报112.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585403198","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585403198?lang=zh_cn&edition=full","pubTime":"2025-11-20 23:46","pubTimestamp":1763653571,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日23时46分，Nuvalent, Inc.股票出现波动，股价快速上涨5.06%。截至发稿，该股报112.55美元/股，成交量20.2582万股，换手率0.26%，振幅5.72%。Nuvalent, Inc.股票所在的生物技术行业中，整体涨幅为1.92%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202346129775dd6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202346129775dd6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NUVL","BK4539"],"gpt_icon":0},{"id":"1106074107","title":"Nuvalent宣布FDA接受Zidesamtinib的新药申请，用于治疗已接受TKI治疗的晚期ROS1阳性NSCLC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1106074107","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106074107?lang=zh_cn&edition=full","pubTime":"2025-11-20 05:21","pubTimestamp":1763587269,"startTime":"0","endTime":"0","summary":"Nuvalent宣布FDA接受Zidesamtinib的新药申请，用于治疗已接受TKI治疗的晚期ROS1阳性NSCLC患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","NUVL"],"gpt_icon":0},{"id":"1121008983","title":"全球股市概览：市场动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1121008983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121008983?lang=zh_cn&edition=full","pubTime":"2025-11-18 07:07","pubTimestamp":1763420851,"startTime":"0","endTime":"0","summary":"最新的市场动态涵盖了股票市场。文章在道琼斯新闻社全天独家发布。现任CEO Mark Allison表示他将至少留任到九月份。与此同时，Elders正在进行寻找潜在接班人的流程。它对Elders的覆盖评级重启，给予“跑赢大盘”的评级，目标价为每股8.25澳元。Elders在周一收盘价为7.41澳元。它维持对New Hope的增持评级。销售额增长2.2%，息税折旧摊销前利润增长12%，净利润增长34%。Catapult Sports报告上半年营业利润增长56%。Brands股价上涨0.2%，至149.28美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360997.AUD","LU0314106906.USD","LU1935043023.USD","LU0225283273.USD","LU0511384066.AUD","LU0724617625.USD","LU0354030438.USD","LU0784384876.USD","LU1582987324.SGD","LU1699723380.USD","LU1674673691.USD","LU0308772762.SGD","LU0979878070.USD","LU1935043536.SGD","LU2403377893.USD","IE00B19Z9505.USD","SG9999017495.SGD","LU1046421795.USD","LU0158827781.USD","LU2347655073.USD","BK4585","LU0127658192.USD","SG9999015358.SGD","LU1934455863.HKD","LU0077335932.USD","LU2065169927.USD","IE0005OL40V9.USD","SG9999001424.SGD","LU2023250504.SGD","LU2089283258.USD","LU1301847155.USD","IE00B775SV38.USD","LU1571399168.USD","LU0154236417.USD","LU2092937148.SGD","LU1363072403.SGD","LU1551013425.SGD","LU2023251221.USD","BK4127","LU0823434740.USD","IE0004086264.USD","IE0004445015.USD","LU0006306889.USD","LU0868494708.USD","LU0070217475.USD","LU0957791311.USD","LU1037948541.HKD","SG9999014567.USD","LU2191332357.HKD","BK4534","SG9999015952.SGD","LU2462157665.USD","LU1244550221.USD","LU0011850046.USD","LU0784385840.USD","LU2543165471.USD","LU1989771016.USD","IE00BLSP4452.SGD","IE00BKDWB100.SGD","LU0345770308.USD","LU2456880835.USD","LU0048584097.USD","LU0314104364.USD","LU1674673428.USD","LU2097344431.USD","LU2087621335.USD","LU1116320737.USD","BK4139","SG9999014906.USD","LU0109392836.USD","LU0210528500.USD","IE000KEQY171.SGD","LU1069344957.HKD","LU0265550359.USD","IE00BWXC8680.SGD","LU1244550577.SGD","SG9999014575.USD","LU2471134523.USD","IE0003U64NQ7.SGD","LU2361044865.SGD","LU1732800096.USD","LU0726765562.USD","LU0912757837.SGD","LU1084165304.USD","LU0689626769.HKD","LU2430703251.USD","MS","LU1496350171.SGD","LU0267386448.USD","SG9999015945.SGD","BK4533","LU1815333072.USD","LU1242518931.SGD","LU0345768153.USD","IE00BJTD4N35.SGD","LU0868494617.USD","LU1718418525.SGD","LU1291159041.SGD","IE00B4YYXB79.USD","LU0795875169.SGD","LU1162221912.USD","LU1934455277.USD","LU2505996681.GBP","LU0661504455.SGD","LU0056508442.USD","LU2505996509.AUD","LU0444971666.USD","LU1206713676.USD","IE00BFSS8Q28.SGD","LU0964807845.USD","LU0345768740.USD","LU0251132253.USD","LU2756315318.SGD","LU1316542783.SGD","LU2087625088.SGD","LU1868836591.USD","LU0256863902.USD","LU2242650005.HKD","LU0784385170.HKD","SG9999000418.SGD","IE0009G5SDU7.USD","BK4550","LU2092627202.USD","LU0672654240.SGD","SG9999018857.SGD","LU2746668461.USD","LU0820561818.USD","LU1989772923.USD","LU0786609619.USD","LU2083900584.USD","LU2236285917.USD","LU0472753341.HKD","LU1815336760.USD","LU1066051225.USD","LU0788109477.HKD","LU2452424414.USD","LU1261432733.SGD","LU2471134879.HKD","LU0345769128.USD","IE00BBT3K403.USD","LU2168564495.EUR","IE00B5949003.HKD","IE0004445239.USD","LU0787776722.HKD","LU1145028129.USD","IE0001KFT4U8.USD","LU0053666078.USD","LU0466842654.USD","IE00B3SWFQ91.USD","LU1506573853.SGD","LU2552382058.USD","LU0256863811.USD","LU0957808578.USD","LU2213496289.HKD","LU1127390331.HKD","LU0203202063.USD","BK4501","LU0354030511.USD","LU2458330243.SGD","LU0320765646.SGD","BK4566","LU2106854487.HKD","LU0170899867.USD","LU1267930730.SGD","LU1629891620.HKD","LU0943347566.SGD","LU1989764664.SGD","IE00B1XK9C88.USD","LU2458330169.SGD","SG9999014559.SGD","LU2360032135.SGD","LU1244550494.USD","LU2108987350.USD","LU2552382215.SGD","SG9999014898.SGD","LU0082616367.USD","LU0823421416.USD","LU1791710582.SGD","LU2592432038.USD","LU2552382132.HKD","LU2417539215.USD","LU2237443978.SGD","LU1814569148.SGD","LU2381873111.SGD","LU1868836757.USD","LU0234572021.USD","IE00BFSS7M15.SGD","SG9999014880.SGD","LU0238689110.USD","IE00B775H168.HKD","IE00BK4W5M84.HKD","LU2168564149.EUR","LU2237438978.USD","LU1720051108.HKD","LU0289739343.SGD","LU2361045086.USD","LU2750360641.GBP","LU2125154935.USD","LU2461242641.AUD","LU1989772840.SGD","BK4573","LU2265009873.SGD","LU0971096721.USD","BK4581","BK4532","IE00BN8TJ469.HKD","LU0316494557.USD","LU1116320901.HKD","LU0708995401.HKD","LU0456855351.SGD","IE00BSNM7G36.USD","BK4598","LU1839511570.USD","LU2420271590.USD","IE00B3S45H60.SGD","LU0109391861.USD","BK4505","LU0106831901.USD","LU0289961442.SGD","LU2286300806.USD","LU1642822529.SGD","LU1823568750.SGD","LU0106261372.USD","LU1119994496.HKD","LU0784383803.USD","BK4554","LU0203201768.USD","BK4571","LU2487616109.SGD","LU2602419157.SGD","LU1917777945.USD","HK0000320223.HKD","LU0965509010.AUD","LU2430703178.SGD","IE00BJJMRY28.SGD","LU1206712785.SGD","IE00BJJMRX11.SGD","LU0345769631.USD","BK4515","IE000ITXATA3.USD","LU0345770993.USD","LU2028103732.USD","IE000W1ABFV2.USD","LU0444973449.USD","SG9999015986.USD","LU2756315664.SGD","LU0949170772.SGD","NUVL","LU0985320562.USD","LU2125154778.USD","LU1232071149.USD","LU0353189680.USD","LU1366333091.USD","LU2430703095.HKD","LU1934455194.USD","LU0210533765.USD","BK4539","BK4553","LU0158827948.USD","LU0795875086.SGD","SG9999014542.SGD","LU1935042991.SGD","IE00B4JS1V06.HKD","LU0553294199.USD","LU1582986359.USD","BK4507","LU2237443549.SGD","LU0557290698.USD","LU1037948897.HKD","LU2077746001.SGD","MACW.SI","BK4516","IE00BKVL7J92.USD","LU0640476718.USD","LU1668664300.SGD","IE00BJTD4V19.USD","LU0265550946.USD","HK0000320264.USD","SG9999015978.USD","LU2860962120.EUR","LU2271345857.HKD","IE00BN29S564.USD","SG9999014914.USD","LU0057025933.USD","LU1804176565.USD","LU0683600562.USD","LU1548497426.USD","LU0348723411.USD","LU1720051017.SGD","IE00BK4W5L77.USD","LU1778281490.HKD","BK4592","IE00B1BXHZ80.USD","IE0004091025.USD","LU0072462426.USD","LU0215105999.USD","SG9999002232.USD","LU0528227936.USD","IE00B19Z8X17.USD","BK4512","LU2133065610.SGD","LU2065170008.USD","LU2471134952.CNY","LU0889565833.HKD","LU0096362180.USD","LU1066053197.SGD","LU1868836914.USD","LU2023250330.USD","LU0210536198.USD","LU0320765059.SGD","BK4579","IE000YTNTUN2.SGD","LU2023250843.SGD","LU2360106780.USD","LU2347655156.SGD","LU1582986433.USD","IE0009356076.USD","LU0494093205.USD","LU1242518857.USD","LU0079474960.USD","LU2237443895.HKD","LU1791710400.SGD","LU2065171311.SGD","AAPL","IE00B7KXQ091.USD","LU1803068979.SGD","LU0198837287.USD","LU1074936037.SGD","LU0965508806.USD","LU1066051498.USD","LU1280957306.USD","LU1868837136.USD","LU1935042215.USD","LU0545039389.USD","LU1551013342.USD","SG9999018865.SGD","LU1914381329.SGD","LU0234570918.USD","LU0061475181.USD","LU0157215616.USD","LU2896262040.SGD","LU0820561909.HKD","LU1582987597.SGD","LU0080751232.USD","LU2247934214.USD","LU0642271901.SGD","BK4559","LU1496350502.SGD","BK4574","HK0000306701.USD","LU2237443465.HKD","LU2746668974.SGD","LU0965509283.SGD","BK4576","LU2168563687.JPY","SGXZ31699556.SGD","LU0820562030.AUD","LU0069063385.USD","LU1366192091.USD","LU2250418816.HKD","SG9999015341.SGD","LU0823434583.USD","LU0861579265.USD","IE00BZ1G4Q59.USD","LU0823421333.USD","LU0719512351.SGD","GB00BDT5M118.USD","LU1852331112.SGD","LU2063271972.USD","LU2361044949.HKD","LU2089284900.SGD","LU2065171402.SGD","LU0942090050.USD","BK4504","SG9999002224.SGD","IE0034235303.USD","LU0096364046.USD","LU0149725797.USD","LU0061474960.USD","BK4170","LU1989764748.USD","BK4527","LU0949170426.SGD","LU1974910355.USD","LU0124676726.USD","LU0738911758.USD","LU0098860793.USD","LU0323591593.USD","LU1732799900.SGD","LU0417517546.SGD","HK0000306685.HKD","LU1066051811.HKD","LU1935042488.USD","LU1235294995.USD","LU0097036916.USD","LU1868837300.USD","LU2237443382.USD","BK4575","LU2168564065.EUR","LU1003077747.HKD","IE00BLSP4239.USD","LU0965509101.SGD","LU2357305700.SGD","LU0476273544.USD","IE00B19Z8W00.USD","LU2097344357.USD","LU2242649171.HKD","LU0689472784.USD","LU0353189763.USD","LU0882574139.USD","LU2471134796.USD","LU2237443622.USD","BK4588","IE00BJLML261.HKD","LU2168564222.USD","LU2054465674.USD","LU2111349929.HKD","LU1035775433.USD"],"gpt_icon":1},{"id":"1119995847","title":"Nuvalent：计划在预 NDA 会议上与 FDA 讨论 TKI 预治疗 ALK 阳性 NSCLC 人群的关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1119995847","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119995847?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:32","pubTimestamp":1763379171,"startTime":"0","endTime":"0","summary":"Nuvalent：计划在预 NDA 会议上与 FDA 讨论 TKI 预治疗 ALK 阳性 NSCLC 人群的关键数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"gpt_icon":0},{"id":"1100423211","title":"Nuvalent：Neladalkib展现出良好的耐受性安全特征，剂量中断和剂量减少发生率低","url":"https://stock-news.laohu8.com/highlight/detail?id=1100423211","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100423211?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:32","pubTimestamp":1763379169,"startTime":"0","endTime":"0","summary":"Nuvalent：Neladalkib展现出良好的耐受性安全特征，剂量中断和剂量减少发生率低","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"gpt_icon":0},{"id":"1174448154","title":"Nuvalent在253名ALK TKI预处理患者中的ORR为31%，估计18个月时53%的应答者仍保持反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1174448154","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174448154?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:32","pubTimestamp":1763379138,"startTime":"0","endTime":"0","summary":"Nuvalent在253名ALK TKI预处理患者中的ORR为31%，估计18个月时53%的应答者仍保持反应","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NUVL","BK4539"],"gpt_icon":0},{"id":"1146812006","title":"Nuvalent公布ALK阳性晚期非小细胞肺癌TKI预处理患者的ALKOVE-1临床试验Neladalkib的关键数据时间安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1146812006","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146812006?lang=zh_cn&edition=full","pubTime":"2025-11-15 05:02","pubTimestamp":1763154133,"startTime":"0","endTime":"0","summary":"Nuvalent公布ALK阳性晚期非小细胞肺癌TKI预处理患者的ALKOVE-1临床试验Neladalkib的关键数据时间安排","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","BK4539","BK4139"],"gpt_icon":0},{"id":"2582308381","title":"华尔街顶级分析师最新评级报告：美国电话电报公司评级上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2582308381","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582308381?lang=zh_cn&edition=full","pubTime":"2025-11-12 23:05","pubTimestamp":1762959900,"startTime":"0","endTime":"0","summary":"华尔街最受关注、且能影响市场走势的研究评级报告现已汇总一处。KeyBanc 银行将美国电话电报公司的评级从 “行业权重” 上调至 “增持”，目标股价定为 30 美元。伯恩斯坦公司首次覆盖辛塔斯公司，给予 “与大盘持平” 评级，目标股价定为 200 美元。该机构认为，辛塔斯是一家 “优质成长型公司”，但当前股价已处于高位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-12/doc-infxemns6034755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4503","QUIK","BK4598","LU0823417653.USD","BK4507","BBWI","GRAL","BK4141","BK4534","LU1169590202.USD","BK4535","BK4550","BHF","LU1169589451.USD","LU0211326839.USD","LU1621768115.EUR","LU2506951958.HKD","LU2506952170.USD","BK4139","LU1571399168.USD","KMX","NUVL","LU0175139822.USD","PGNY","BK4214","BK4234","LU0650527681.SGD","BK4142","BK4585","CTAS","LU1621767810.EUR","BK4215","CSR","OUT","CVNA","IE00BSNM7G36.USD","BK4137","NTLA","AN","T","LU1621768206.USD","BK4588","BK4548","FND","BK4162","ATAT","BK4200","BK4556","LU1861558580.USD","BK4154"],"gpt_icon":0},{"id":"2579890894","title":"Nuvalent, Inc.跌2.98% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2579890894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579890894?lang=zh_cn&edition=full","pubTime":"2025-10-31 03:37","pubTimestamp":1761853028,"startTime":"0","endTime":"0","summary":"北京时间2025年10月31日03时37分，Nuvalent, Inc.股票出现波动，股价快速跳水2.98%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Intensity Therapeutics, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 涨幅较大，Intensity Therapeutics, Inc.、Cero Therapeutics Holdings, Inc.、Vivosim Labs, Inc.较为活跃，换手率分别为2693.19%、2008.27%、965.04%，振幅较大的相关个股有Intensity Therapeutics, Inc.、Azitra Inc、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为412.14%、58.30%、53.55%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031033708a47e6119&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031033708a47e6119&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NUVL","BK4539"],"gpt_icon":0},{"id":"1105540170","title":"Nuvalent, Inc. - 预计将在2025年底报告Neladalkib在已接受TKI治疗的晚期ALK阳性非小细胞肺癌中的关键临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1105540170","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105540170?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:37","pubTimestamp":1761820632,"startTime":"0","endTime":"0","summary":"Nuvalent, Inc. - 预计将在2025年底报告Neladalkib在已接受TKI治疗的晚期ALK阳性非小细胞肺癌中的关键临床数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"gpt_icon":0},{"id":"1178409484","title":"Nuvalent强调近期管道进展，重申关键预期里程碑，并报告2025年第三季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1178409484","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178409484?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:31","pubTimestamp":1761820272,"startTime":"0","endTime":"0","summary":"Nuvalent强调近期管道进展，重申关键预期里程碑，并报告2025年第三季度财务业绩","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NUVL","BK4539"],"gpt_icon":0},{"id":"2577320626","title":"Nuvalent, Inc.盘中异动 下午盘股价大跌5.08%报92.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577320626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577320626?lang=zh_cn&edition=full","pubTime":"2025-10-23 01:13","pubTimestamp":1761153197,"startTime":"0","endTime":"0","summary":"北京时间2025年10月23日01时13分，Nuvalent, Inc.股票出现波动，股价大幅跳水5.08%。截至发稿，该股报92.24美元/股，成交量28.8741万股，换手率0.40%，振幅5.69%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.54%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023011317a6c86044&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023011317a6c86044&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","NUVL"],"gpt_icon":0},{"id":"2577844129","title":"Nuvalent, Inc.盘中异动 急速上涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577844129","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577844129?lang=zh_cn&edition=full","pubTime":"2025-10-21 01:57","pubTimestamp":1760983070,"startTime":"0","endTime":"0","summary":"北京时间2025年10月21日01时57分，Nuvalent, Inc.股票出现异动，股价快速上涨5.11%。Nuvalent, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。其相关个股中，Replimune Group, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 、Alto Neuroscience, Inc.涨幅较大，Azitra Inc、Genprex, Inc.、Rani Therapeutics Holdings, Inc.较为活跃，换手率分别为1704.75%、1478.37%、303.29%，振幅较大的相关个股有Bio Green Med Solution Inc. 6% Cnv Pfd Usd、Lexaria Bioscience Corp C/Wts 14/01/2026 、Alto Neuroscience, Inc.，振幅分别为140.80%、93.37%、89.80%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102101575094d43e4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102101575094d43e4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL","BK4539","BK4139"],"gpt_icon":0},{"id":"2575745222","title":"Nuvalent, Inc.盘中异动 下午盘股价大跌5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745222","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575745222?lang=zh_cn&edition=full","pubTime":"2025-10-15 01:10","pubTimestamp":1760461854,"startTime":"0","endTime":"0","summary":"北京时间2025年10月15日01时10分，Nuvalent, Inc.股票出现波动，股价急速下跌5.35%。Nuvalent, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Pmgc Holdings Inc.、Astria Therapeutics, Inc.、Senti Biosciences, Inc.涨幅较大，Pmgc Holdings Inc.、Astria Therapeutics, Inc.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为2813.49%、38.90%、38.05%，振幅较大的相关个股有Pmgc Holdings Inc.、Cdt Equity Inc C/Wts 22/09/2028、Cardio Diagnostics Holdings Inc C/Wts To Pur Com，振幅分别为55.85%、38.33%、37.50%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101501105494c9207e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101501105494c9207e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","NUVL","BK4139"],"gpt_icon":0},{"id":"1167884170","title":"Nuvalent, Inc.在2025年世界肺癌大会上公布Zidesamtinib治疗既往接受TKI治疗的晚期ROS1阳性非小细胞肺癌患者的Arros-1临床试验关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1167884170","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167884170?lang=zh_cn&edition=full","pubTime":"2025-09-07 16:46","pubTimestamp":1757234776,"startTime":"0","endTime":"0","summary":"Nuvalent, Inc.在2025年世界肺癌大会上公布了Zidesamtinib治疗既往接受TKI治疗的晚期ROS1阳性非小细胞肺癌患者的Arros-1临床试验关键数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","BK4139","BK4539"],"gpt_icon":0},{"id":"2518202206","title":"Nuvalent, Inc.盘中异动 急速下挫5.08%报67.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518202206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518202206?lang=zh_cn&edition=full","pubTime":"2025-03-11 03:13","pubTimestamp":1741634026,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日03时13分，Nuvalent, Inc.股票出现波动，股价急速下跌5.08%。截至发稿，该股报67.46美元/股，成交量71.6696万股，换手率1.00%，振幅3.74%。Nuvalent, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311031346a26aa563&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311031346a26aa563&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","NUVL"],"gpt_icon":0},{"id":"2517162594","title":"Nuvalent, Inc.2024财年实现净利润-2.61亿美元，同比减少107.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162594","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162594?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276864,"startTime":"0","endTime":"0","summary":"3月7日，Nuvalent, Inc.公布财报，公告显示公司2024财年净利润为-2.61亿美元，同比减少107.14%；其中营业收入为0.00美元，每股基本收益为-3.93美元。从资产负债表来看，Nuvalent, Inc.总负债71.96百万美元，其中短期债务0.00美元，资产负债比为0.16，流动比率为0.21。机构评级：截至2025年3月7日，当前有11家机构对Nuvalent, Inc.目标价做出预测，其中目标均价为113.73美元，其中最低目标价为100.00美元，最高目标价为137.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000122abeb8d0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000122abeb8d0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL"],"gpt_icon":0},{"id":"1194057199","title":"Nuvalent 2024年第四季度每股亏损1.05美元，超出分析师预期的1.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194057199","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194057199?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:40","pubTimestamp":1740656431,"startTime":"0","endTime":"0","summary":"Nuvalent报告其每股季度亏损1.05美元，超出分析师普遍预期的1.08美元，比预期高出2.78%。与去年同期的每股亏损0.62美元相比，亏损增加了69.35%。以上内容来自Benzinga Earnings专栏，原文如下：Nuvalent reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.78 percent. This is a 69.35 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nuvalent 2024年第四季度每股亏损1.05美元，超出分析师预期的1.08美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvalent.com","stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.0237},{"period":"3month","weight":-0.0496},{"period":"6month","weight":0.3571},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0332}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nuvalent, Inc.于2017年1月25日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。该公司利用团队在化学和基于结构的药物设计方面的深厚专业知识，开发创新的小分子，其设计旨在克服现有疗法对临床证明的激酶靶点的限制。目前可用的激酶抑制剂面临的限制可能包括（i）激酶耐药性，或激酶靶点出现新的突变，从而能够对现有疗法产生耐药性，（ii）激酶选择性，或现有疗法可能抑制结构相似的激酶靶点并导致脱靶不良事件，以及（iii）有限的脑外显率，或该疗法治疗已经扩散或转移到大脑的疾病的能力。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":-0.027036},{"month":2,"riseRate":0.8,"avgChangeRate":0.022503},{"month":3,"riseRate":0,"avgChangeRate":-0.092764},{"month":4,"riseRate":0.5,"avgChangeRate":0.024196},{"month":5,"riseRate":0.25,"avgChangeRate":-0.006145},{"month":6,"riseRate":1,"avgChangeRate":0.177709},{"month":7,"riseRate":1,"avgChangeRate":0.08966},{"month":8,"riseRate":0.6,"avgChangeRate":0.217715},{"month":9,"riseRate":0.8,"avgChangeRate":0.02208},{"month":10,"riseRate":0.8,"avgChangeRate":0.213383},{"month":11,"riseRate":0.6,"avgChangeRate":0.048468},{"month":12,"riseRate":0.2,"avgChangeRate":-0.069265}],"exchange":"NASDAQ","name":"Nuvalent, Inc.","nameEN":"Nuvalent, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nuvalent, Inc.(NUVL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nuvalent, Inc.,NUVL,Nuvalent, Inc.股票,Nuvalent, Inc.股票老虎,Nuvalent, Inc.股票老虎国际,Nuvalent, Inc.行情,Nuvalent, Inc.股票行情,Nuvalent, Inc.股价,Nuvalent, Inc.股市,Nuvalent, Inc.股票价格,Nuvalent, Inc.股票交易,Nuvalent, Inc.股票购买,Nuvalent, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nuvalent, Inc.(NUVL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}